Studies on 4-benzyl-1-methyl-1,2,3,6-tetrahydropyridine, a nonneurotoxic analogue of the parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Studies on 4-benzyl-1-methyl-1,2,3,6-tetrahydropyridine, a nonneurotoxic analogue of the parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
复制标题
4-苄基-1-甲基-1,2,3,6-四氢吡啶的研究,帕金森病诱导剂 1-甲基-4-苯基-1,2,3,6-四氢吡啶的非神经毒性类似物。
DOI:
10.1021/tx00014a008
复制
发表时间:
1990
影响因子:
4.1
通讯作者:
CastagnoliJr,N
中科院分区:
文献类型:
--
作者:
Naiman,N;Rollema,H;Johnson,E;CastagnoliJr,N
Previous reports indicate that 4-benzyl-l-methyl-l, 2, 3, 6-tetrahydropyridine (BMTP), the benzyl analogue of the Parkinsonian inducing neurotoxinl-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine (MPTP), is not neurotoxic in the C-57 black mouse even when administered at a dose 10 times greater than the dose of MPTP required to cause an 85% depletion of neostriatal dopamine. Intrastriatal microdialysis in the rat with the corresponding 4-benzyl-l-methylpyridinium ion BMP"* 1" for 60 min, however, causes nerve terminal destruction similar to that observed following a 15-min perfusion with the l-methyl-4-phenylpyridinium ion MPP+, the monoamine oxidase B (MAO-B) generated metabolite derived from MPTP. With the aid of purified beef liver MAO-B and synthetic standards, we observed the efficient and quantitative conversion of BMTP to the corresponding 2, 3-dihydropyridinium intermediate BMDP+, which underwent further, but incomplete, oxidation to BMP" 1". These MPTP-type properties point to in vivo effects, such as pharmacokinetic parameters and/or alternative metabolic pathways, to account forBMTP’s lack of neurotoxicity.